Consequently, cisplatin resistance was reduced, as determined by the Cck8 assay (Figure 4C) and apoptosis assay (Figure 4D) in vitro and by tumor growth and tumor weight in vivo (Figures 4Ei–iii), upon inactivation of the MEK/ERK pathway by Mek1/2-knockdown. The gene discussed is MAPK1; the disease is neoplasm.